131 related articles for article (PubMed ID: 12634730)
1. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning.
Valcárcel D; Martino R; Caballero D; Mateos MV; Pérez-Simón JA; Canals C; Fernández F; Bargay J; Muñiz-Díaz E; Gonzalez M; San Miguel JF; Sierra J
Bone Marrow Transplant; 2003 Mar; 31(5):387-92. PubMed ID: 12634730
[TBL] [Abstract][Full Text] [Related]
2. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.
Martino R; Caballero MD; de la Serna J; Díez-Martín JL; Urbano-Ispízua A; Tomás JF; Odriozola J; León A; Canals C; San Miguel J; Sierra J
Bone Marrow Transplant; 2002 Jul; 30(2):63-8. PubMed ID: 12132043
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
6. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
[TBL] [Abstract][Full Text] [Related]
7. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
8. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
10. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
11. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.
Antin JH; Childs R; Filipovich AH; Giralt S; Mackinnon S; Spitzer T; Weisdorf D
Biol Blood Marrow Transplant; 2001; 7(9):473-85. PubMed ID: 11669214
[TBL] [Abstract][Full Text] [Related]
12. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
13. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
14. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
15. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
16. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA; Díez-Campelo M; Martino R; Brunet S; Urbano A; Caballero MD; de León A; Valcárcel D; Carreras E; del Cañizo MC; López-Fidalgo J; Sierra J; San Miguel JF
Br J Haematol; 2005 Aug; 130(3):394-403. PubMed ID: 16042689
[TBL] [Abstract][Full Text] [Related]
17. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
[TBL] [Abstract][Full Text] [Related]
18. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
19. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
Chan GW; Gorgun G; Miller KB; Foss FM
Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
[TBL] [Abstract][Full Text] [Related]
20. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
